[1]
|
Linos, E., Swetter, S.M., Cockburn, M.G., Colditz, G.A. and Clarke, C.A. (2009) Increasing Burden of Melanoma in the United States. Journal of Investigative Dermatology, 129, 1666-1674. http://dx.doi.org/10.1038/jid.2008.423
|
[2]
|
Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. http://dx.doi.org/10.3322/caac.21254
|
[3]
|
Balsh, C.M., Gershenwald, J.E., Soong, S.-J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. (2009) Final Version of the 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology, 27, 6199-6206. http://dx.doi.org/10.1200/JCO.2009.23.4799
|
[4]
|
Ilieva, K.M., Correa, I., Josephs, D.H., Karagiannis P., Egbuniwe, I.U., Cafferkey, M.I., et al. (2014) Effects of BRAF Mutations and BRAF Inhibition on Immune Responses in Melanoma. Molecular Cancer Therapeutics, 3, 2769-2783.
|
[5]
|
Mervic, L. (2012) Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women. PLoS One, 7, e32955. http://dx.doi.org/10.1371/journal.pone.0032955
|
[6]
|
Korn, E.L., Liu, P.Y., Lee, S.J., Chapman, J.-A., Niedzwiecki, D., Suman, V.J., et al. (2008) Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. Journal of Clinical Oncology, 26, 527-534. http://dx.doi.org/10.1200/JCO.2007.12.7837
|
[7]
|
Manola, J., Atkins, M., Ibrahim, J. and Kirkwood, J. (2000). Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials. Journal of Clinical Oncology, 18, 3782-3793.
|
[8]
|
Hodi, F.S., O’Day, S.J., McDermott, D.V., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363, 711-723. http://dx.doi.org/10.1056/NEJMoa1003466
|
[9]
|
Robert, C., Karaszewska, B., Shachter, J, Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. (2015) Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. New England Journal of Medicine, 372, 30-39. http://dx.doi.org/10.1056/NEJMoa1412690
|
[10]
|
Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K. and Hamid, O. (2015) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 10, 1889-1894. http://dx.doi.org/10.1200/JCO.2014.56.2736
|
[11]
|
Margolin, K.A., Tarhini, A., Rao, S., Katyal, M., Chang, I.-F., Johnson D.B., et al. (2015) Effectiveness and Safety of Ipilimumab Therapy in Melanoma: Evidence from a US Multisite Observational Chart Review. Journal of Community and Supportive Oncology, 13, 131-138. http://dx.doi.org/10.12788/jcso.0124
|
[12]
|
Guy, G.P., Ekwueme, D.U., Tangka, F.K. and Richardson, L.C. (2012) Melanoma Treatment Costs: A Systematic Review of the Literature, 1990-2011. American Journal of Preventive Medicine, 43, 537-545. http://dx.doi.org/10.1016/j.amepre.2012.07.031
|
[13]
|
Tsao, H., Rogers, G.S. and Sober, A.J. (1998) An Estimate of the Annual Direct Cost of Treating Cutaneous Melanoma. Journal of the American Academy of Dermatologists, 38, 669-680. http://dx.doi.org/10.1016/S0190-9622(98)70195-1
|
[14]
|
Housman, T.S., Feldman, S.R., Williford, P.M., Fleischer Jr., A.B., Goldman, N.D., Acostamadiedo, J.M., et al. (2003) Skin Cancer Is among the Most Costly of all Cancers to Treat in a Medicare Population. Journal of the American Academy of Dermatologists, 48, 425-429. http://dx.doi.org/10.1067/mjd.2003.186
|
[15]
|
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
|
[16]
|
Ingenix (2011) National Fee Analyzer. Ingenix, Eden Prairie.
|
[17]
|
Healthcare Cost and Utilization Project (2012) Overview of the National (Nationwide) Inpatient Sample (NIS). Agency for Healthcare Research and Quality, Rockville. http://www.hcup-us.ahrq.gov/nisoverview.jsp
|
[18]
|
Davis, K.L., Mitra, D., Kotapati, S., Ibrahim, R. and Wolchok, J.D. (2009) Direct Economic Burden of High-Risk and Metastatic Melanoma in the Elderly: Evidence from the SEER-Medicare Linked Database. Applied Health Economics and Health Policy, 7, 31-41. http://dx.doi.org/10.1007/BF03256140
|
[19]
|
Centers for Medicare & Medicaid Services (2014) ASP Drug Pricing Files, April 2014 Update. http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/Apr-14-ASP-Pricing-File.zip
|
[20]
|
Red Book Online. Truven Health Analytics, Inc., Greenwood Village. (Updated Periodically) http://www.micromedexsolutions.com
|
[21]
|
US Bureau of Labor Statistics (2014) Consumer Price Index; Medical Component. http://www.bls.gov/CPI
|
[22]
|
Reyes, C., DaCosta Byfield, S., Linke, R., Satram-Hoang, S. and Teitelbaum, A.H. (2013) The Burden of Metastatic Melanoma: Treatment Patterns, Healthcare Use (Utilization), and Costs. Melanoma Research, 23, 159-166. http://dx.doi.org/10.1097/CMR.0b013e32835e58d6
|
[23]
|
Oster, G., Taneja, C., Penrod, J.R., Yang, A.S. and Edelsberg, J. (2011) Economic Burden of Advanced Melanoma: Findings from a Large US Health Insurance Database. Value in Health, 14, A507. http://dx.doi.org/10.1016/j.jval.2011.08.1493
|
[24]
|
Hillner, B.E., Kirkwood, J.M. and Agarwala, S.S. (2001) Burden of Illness Associated with Metastatic Melanoma: An Audit of 100 Consecutive Referral Center Cases. Cancer, 91, 1814-1821. http://dx.doi.org/10.1002/1097-0142(20010501)91:9<1814::AID-CNCR1201>3.0.CO;2-W
|
[25]
|
Macahilig, C.P., Botteman, M., Prinz, J.M., Yang, A.S. and Penrod, J.R. (2011) Patterns of Care and Healthcare Utilization of US Advanced Melanoma Patients: Evidence from a Medical Chart Review. Poster Presented at Perspectives in Melanoma XV, New York, 16-17 September 2011.
|
[26]
|
Weber, J.S., Minor, D.R., D’Angelo, S.P., Hodi, F.S., Gutzmer, R. and Neyns, B. (2014) A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) versus Investigator’s Choice Chemotherapy (ICC) in Patients with Advanced Melanoma after Prior Anti-CTLA-4 Therapy. Proceedings of the European Society for Medical Oncology Congress, Madrid, 26-30 September 2014.
|
[27]
|
Yabroff, K.R., Lamont, E.B., Mariotto, A., Warren, J.L., Topor, M., Meekins, A., et al. (2008) Cost of Care for Elderly Cancer Patients in the United States. Journal of the National Cancer Institute, 100, 630-641. http://dx.doi.org/10.1093/jnci/djn103
|
[28]
|
Mariotto, A.B., Yabroff, K.R., Shao, Y., Feuer, E.J. and Brown, M.L. (2011) Projections of the Cost of Cancer Care in the United States: 2010-2020. Journal of the National Cancer Institute, 103, 117-128. http://dx.doi.org/10.1093/jnci/djq495
|